Diabetes and Vascular Research Centre, University of Exeter, Exeter, Devon, UK
Academic Department of Healthcare for Older People, Royal Devon and Exeter NHS Foundation Trust, Exeter, Devon, UK.
BMJ Open. 2021 Sep 6;11(9):e043253. doi: 10.1136/bmjopen-2020-043253.
Transient ischaemic attacks (TIA) and minor strokes are important risk factors for further vascular events. We explored the role of albumin creatinine ratio (ACR) in improving risk prediction after a first event.
Rapid access stroke clinics in the UK.
2202 patients attending with TIA or minor stroke diagnosed by the attending stroke physician, able to provide a urine sample to evaluate ACR using a near-patient testing device.
Primary outcome was major adverse cardiac events (MACE: recurrent stroke, myocardial infarction or cardiovascular death) at 90 days. The key secondary outcome was to determine whether urinary ACR could contribute to a risk prediction tool for use in a clinic setting.
151 MACE occurred in 144 participants within 90 days. Participants with MACE had higher ACR than those without. A composite score awarding a point each for age >80 years, previous stroke/TIA and presence of microalbuminuria identified those at low risk and high risk. 90% of patients were at low risk (scoring 0 or 1). Their 90-day risk of MACE was 5.7%. Of the remaining 'high-risk' population (scoring 2 or 3) 12.4% experienced MACE over 90 days (p<0.001 compared with the low-risk population). The need for acute admission in the first 7 days was twofold elevated in the high-risk group compared with the low-risk group (3.23% vs 1.43%; p=0.05). These findings were validated in an independent historic sample.
A risk score comprising age, previous stroke/TIA and microalbuminuria predicts future MACE while identifying those at low risk of a recurrent event. This tool shows promise in the risk stratification of patients to avoid the admission of low-risk patients.
短暂性脑缺血发作(TIA)和小中风是进一步发生血管事件的重要危险因素。我们探讨了白蛋白肌酐比值(ACR)在首次发作后改善风险预测的作用。
英国快速通道卒中诊所。
2202 名 TIA 或由就诊卒中医生诊断为小中风的患者,能够提供尿液样本,使用床边检测设备评估 ACR。
主要结局为 90 天内的主要不良心脏事件(MACE:复发性卒中、心肌梗死或心血管死亡)。关键次要结局是确定尿 ACR 是否有助于在诊所环境中使用的风险预测工具。
144 名参与者中有 151 名在 90 天内发生了 151 次 MACE。发生 MACE 的患者的 ACR 高于未发生 MACE 的患者。一项复合评分,对年龄>80 岁、既往卒中/TIA 和微量白蛋白尿各计 1 分,确定了低危和高危患者。90%的患者为低危(评分 0 或 1)。他们 90 天内 MACE 的风险为 5.7%。在其余“高危”人群(评分 2 或 3)中,12.4%的患者在 90 天内发生 MACE(与低危人群相比,p<0.001)。高危组在急性期(第 1 天至第 7 天)的住院需求比低危组高两倍(3.23%比 1.43%;p=0.05)。这些发现得到了独立历史样本的验证。
包含年龄、既往卒中/TIA 和微量白蛋白尿的风险评分可预测未来的 MACE,同时识别出发生复发性事件风险较低的患者。该工具在对患者进行风险分层以避免低危患者入院方面具有应用前景。